Symic Biomedical Granted $1.5 Million by NIH to Develop Proteoglycan Mimetic Therapy for Vascular Access Failure in ESRD
News
Symic Biomedical, Inc., a company focused on developing therapeutics that offer an exciting and biologically innovative approach to treating disease, announced it received a Phase II SBIR grant from the National ... Read more